Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite being present in up to 1% of the population, few controlled trials have examined the efficacy of treatments for bipolar II depression. Pooled data are presented from four placebo-controlled studies (BOLDER I [5077US/0049] and II [D1447C00135]; EMBOLDEN I [D1447C00001] and II [D1447C00134]) that evaluated the efficacy of quetiapine monotherapy for depressive episodes in patients with bipolar II disorder. METHODS: All studies included an 8-week, double-blind treatment phase in which patients were randomly assigned to treatment with quetiapine 300 mg/day, quetiapine 600 mg/day, or placebo. Outcome measures included the change from baseline in MADRS total score at week 8, effect sizes, and MADRS response and remission rates. RESULTS AND DISCUSSION: Improvements in mean MADRS total scores from baseline to week 8 were significantly greater with quetiapine 300 and 600 mg/day (-15.58 [n = 283] and -14.88 [n = 289]; p < 0.001) compared with placebo (-11.61 [n = 204]). The MADRS effect sizes were 0.44 for quetiapine 300 mg/day and 0.47 for 600 mg/day (p < 0.001 vs placebo). Significantly higher proportions of patients receiving quetiapine, at both doses, than placebo-treated patients achieved response and remission at week 8 (p < 0.01). Common adverse events associated with quetiapine (both doses) included dry mouth, somnolence, sedation, dizziness, and headache. Rates of mania and hypomania were similar for quetiapine and placebo. Quetiapine monotherapy demonstrated significant efficacy compared with placebo and was generally well tolerated in the treatment of bipolar II depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pooled analyses of five identically designed trials demonstrated that quetiapine was superior to placebo, and moreover was equally effective for acute depression in BDI and BDII.243, 437”
From Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [437]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 4×
“Depression is the prevailing phase of illness in patients with bipolar II disorder (Judd et al. 2003; Kupka et al. 2007).”
MethodInfluentialA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“The primary efficacy outcome measure in all four studies was the change from baseline to week 8 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score (Montgomery and Asberg 1979), and this is consequently utilized in the current post hoc analysis.”
MethodThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 3×
“…included the change in MADRS individual items, MADRS response (defined as a decrease from baseline of ≥ 50% in MADRS total score) and remission (defined as MADRS total score of ≤ 12) rates, HAM-D total scores and Hamilton Rating Scale for Anxiety (Hamilton 1959) (HAM-A) total scores at week 8.”
MethodInfluentialDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 2×
“quired to have a Hamilton Rating Scale for Depression (Hamilton 1960) (HAM-D) total score ≥20, a HAM-D item 1 (depressed mood) score ≥2, and a Young Mania Rating Scale (Young et al. 1978) (YMRS) score ≤12.”
MethodPrevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.12 · Cited by 2,627 · cited 1×
“Among patients with bipolar II disorder, the risk of suicide, comorbidity, and role impairment is generally comparable with that of bipolar I disorder (Angst et al. 2010; Merikangas et al. 2011; Suppes and Dennehy 2002; Valtonen et al. 2005).”
BackgroundMerikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399 · cited 2×
“(Merikangas et al. 2007).”
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationJudd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 2×
“Depression is the prevailing phase of illness in patients with bipolar II disorder (Judd et al. 2003; Kupka et al. 2007).”
BackgroundYatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citation
Research works printed but not linked: 2
- Angst J, Gamma A, Azorin JM, Bowden CL, Perugi G, Vieta E, Young AH: Evidence-based efforts to re-define bipolar disorders. Bipolar Disord 2011,13( Suppl 1):14.
- Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: treatment of bipolar disorder. Postgraduate Med Special Report 2004, 2004: 1–120.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationDiagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 202
Swartz, H. A., Rucci, P., Thase, M. E., Wallace, M. L., Carretta, E., Celedonia, K. L., & Frank, E. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11027 · Cited by 84
Self-citationTreatment of bipolar disorder: Review of evidence regarding quetiapine and lithium
Ketter, T. A., Miller, S., Dell’Osso, B. M., & Wang, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.002 · Cited by 55
Efficacy of bright light therapy in bipolar depression
Yorguner Kupeli, N., Bulut, N. S., Carkaxhiu Bulut, G., Kurt, E., & Kora, K. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2017.12.020 · Cited by 51
Metadata
- Authors
- Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W.
- Affiliations
- King's College London (GB)
- University Hospitals Cleveland Medical Center (US)
- AstraZeneca (Sweden) (SE)
- Mental Health Research Institute (AU)
- Lindner Center of HOPE (US)
- University of Pennsylvania (US)
- VA Palo Alto Health Care System (US)
- AstraZeneca (United States) (US)
- Corresponding author
- Young, Allan H
- Venue
- International Journal of Bipolar Disorders
- Published
- 2013-07-04
- Volume
- 1
- Issue
- 1
- Pages
- 10-10
- ISSN
- 2194-7511 (ISSN-L)
- PMC
- PMC4230312
- OpenAlex
- W2104877916
- Cited by
- 35
- References
- 61
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 6 · 2015: 3 · 2014: 6
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- International Journal of Bipolar Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- quetiapine, bipolar II depression, bipolar II disorder, monotherapy, atypical antipsychotics, antidepressant efficacy, remission, response rate, adverse events, dose comparison, Montgomery-Asberg Depression Rating Scale
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. https://app.cochat.ai/papers/10.1186/2194-7511-1-10
- The paper
- Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., & Earley, W. (2013). Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International Journal of Bipolar Disorders. https://doi.org/10.1186/2194-7511-1-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.